Ad
BGNE Quote Trading Chart BeiGene Ltd.
home / stock / bgne / bgne quote
Quote | BeiGene Ltd. (NASDAQ:BGNE)
| Last: | $184.38 |
|---|---|
| Change Percent: | 0.31% |
| Open: | $186.92 |
| Close: | $184.38 |
| High: | $187.64 |
| Low: | $183.26 |
| Volume: | 405,605 |
| Last Trade Date Time: | 12/11/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
BGNE Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $184.38 | $186.92 | $184.38 | $187.64 | $183.26 | 405,605 | 12-11-2024 |
| $187.5 | $195.52 | $187.5 | $196.96 | $183.2924 | 1,260,783 | 12-10-2024 |
| $207.62 | $209.1 | $207.62 | $211 | $203.585 | 513,042 | 12-09-2024 |
| $205.62 | $207.72 | $205.62 | $209.46 | $204.085 | 348,989 | 12-06-2024 |
| $201.66 | $204.47 | $201.66 | $204.99 | $200.005 | 254,671 | 12-05-2024 |
| $199.09 | $203.37 | $199.09 | $206.425 | $198.7 | 339,750 | 12-04-2024 |
| $206.01 | $206.22 | $206.01 | $208.23 | $202.635 | 395,221 | 12-03-2024 |
| $205.75 | $214.89 | $205.75 | $216.73 | $200 | 2,095,602 | 12-02-2024 |
| $215 | $215.13 | $215 | $216.37 | $211.365 | 258,633 | 11-29-2024 |
| $206.16 | $201.31 | $206.16 | $210.62 | $201.03 | 341,342 | 11-28-2024 |
| $206.16 | $201.31 | $206.16 | $210.62 | $201.03 | 341,342 | 11-27-2024 |
| $192.11 | $190.2 | $192.11 | $192.17 | $186.52 | 308,162 | 11-26-2024 |
| $190.3 | $192.03 | $190.3 | $194.98 | $188.14 | 276,415 | 11-25-2024 |
| $190.51 | $190.94 | $190.51 | $192.9 | $189.01 | 222,704 | 11-22-2024 |
| $194.56 | $196.09 | $194.56 | $197.48 | $191.41 | 221,472 | 11-21-2024 |
| $194.26 | $195 | $194.26 | $198.48 | $192 | 344,281 | 11-20-2024 |
| $187.77 | $188.24 | $187.77 | $190.085 | $187.19 | 238,525 | 11-19-2024 |
| $187.69 | $186.92 | $187.69 | $188.32 | $184.49 | 444,597 | 11-18-2024 |
| $189.23 | $187.79 | $189.23 | $191.45 | $186.16 | 273,933 | 11-15-2024 |
| $193.29 | $193.58 | $193.29 | $195.64 | $191.255 | 213,477 | 11-14-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, further solidifying its position as the leader in new patient starts in both frontline and relapse...
-
About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely to be efficacious Campaign highlights national treatment guidelines supporting targeted t...
-
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will host an investor webcast on December 16, 2024 at 8:30 am EST. The Company’s R&D leadership team will provide an update on...